Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

profileAnn Mullally, M.D.

TitleAssistant Professor of Medicine
InstitutionBrigham and Women's Hospital
DepartmentMedicine
AddressBrigham and Women's Hospital
Karp Rsch Bldg, 5.125
75 Francis St
Boston MA 02115
Phone617/355-9002
Fax617/632-5167
vCardDownload vCard (login for email)

Collapse Mentoring 
Collapse completed student projects
Effects of Mutant Calreticulin on Megakaryopoiesis in JAK2-unmutated Myeloproliferative Neoplasms
Summer, 05/27/14 - 08/29/14

Collapse Research 
Collapse research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
R01HL131835     (MULLALLY, ANN)Aug 1, 2016 - May 31, 2021
NIH/NHLBI
Functional and Molecular Dissection of Mutant Calreticulin in Myeloproliferative Neoplasms
Role: Principal Investigator

K08HL109734     (MULLALLY, ANN)Aug 10, 2011 - Jul 31, 2016
NIH/NHLBI
Functional and Molecular Dissection of Myeloproliferative Neoplasm Stem Cells
Role: Principal Investigator

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Mullally A. Kinase Inhibitors in the Treatment of Myeloid Malignancies. Hematol Oncol Clin North Am. 2017 Aug; 31(4):ix-x. PMID: 28673398.
    View in: PubMed
  2. Hobbs GS, Rozelle S, Mullally A. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms. Hematol Oncol Clin North Am. 2017 Aug; 31(4):613-626. PMID: 28673391.
    View in: PubMed
  3. Schneider RK, Mullally A, Dugourd A, Peisker F, Hoogenboezem R, Van Strien PMH, Bindels EM, Heckl D, Büsche G, Fleck D, Müller-Newen G, Wongboonsin J, Ventura Ferreira M, Puelles VG, Saez-Rodriguez J, Ebert BL, Humphreys BD, Kramann R. Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target. Cell Stem Cell. 2017 Jun 01; 20(6):785-800.e8. PMID: 28457748.
    View in: PubMed
  4. Mead AJ, Mullally A. Myeloproliferative neoplasm stem cells. Blood. 2017 Mar 23; 129(12):1607-1616. PMID: 28159736.
    View in: PubMed
  5. Nishanth G, Wolleschak D, Fahldieck C, Fischer T, Mullally A, Perner F, Schnöder TM, Just S, Heidel FH, Schlüter D. Gain of function in Jak2V617F-positive T-cells. Leukemia. 2017 Apr; 31(4):1000-1003. PMID: 28074070.
    View in: PubMed
  6. Mullally A. Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms. Pathologe. 2016 Nov; 37(Suppl 2):175-179. PMID: 27796499.
    View in: PubMed
  7. Obeng EA, Chappell RJ, Seiler M, Chen MC, Campagna DR, Schmidt PJ, Schneider RK, Lord AM, Wang L, Gambe RG, McConkey ME, Ali AM, Raza A, Yu L, Buonamici S, Smith PG, Mullally A, Wu CJ, Fleming MD, Ebert BL. Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. Cancer Cell. 2016 Sep 12; 30(3):404-17. PMID: 27622333; PMCID: PMC5023069 [Available on 09/12/17].
  8. Elf S, Abdelfattah NS, Chen E, Perales-Patón J, Rosen EA, Ko A, Peisker F, Florescu N, Giannini S, Wolach O, Morgan EA, Tothova Z, Losman JA, Schneider RK, Al-Shahrour F, Mullally A. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. Cancer Discov. 2016 Apr; 6(4):368-81. PMID: 26951227; PMCID: PMC4851866 [Available on 04/01/17].
  9. Chen E, Ahn JS, Sykes DB, Breyfogle LJ, Godfrey AL, Nangalia J, Ko A, DeAngelo DJ, Green AR, Mullally A. RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability. Cell Rep. 2015 Dec 22; 13(11):2345-52. PMID: 26686625; PMCID: PMC4691544.
  10. Wen QJ, Yang Q, Goldenson B, Malinge S, Lasho T, Schneider RK, Breyfogle LJ, Schultz R, Gilles L, Koppikar P, Abdel-Wahab O, Pardanani A, Stein B, Gurbuxani S, Mullally A, Levine RL, Tefferi A, Crispino JD. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat Med. 2015 Dec; 21(12):1473-80. PMID: 26569382; PMCID: PMC4674320.
  11. Schram AM, Comstock P, Campo M, Gorovets D, Mullally A, Bodio K, Arnason J, Berliner N. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol. 2016 Feb; 172(3):412-9. PMID: 26537747.
    View in: PubMed
  12. Schram AM, Campigotto F, Mullally A, Fogerty A, Massarotti E, Neuberg D, Berliner N. Marked hyperferritinemia does not predict for HLH in the adult population. Blood. 2015 Mar 05; 125(10):1548-52. PMID: 25573993.
    View in: PubMed
  13. Ishikawa Y, Maeda M, Pasham M, Aguet F, Tacheva-Grigorova SK, Masuda T, Yi H, Lee SU, Xu J, Teruya-Feldstein J, Ericsson M, Mullally A, Heuser J, Kirchhausen T, Maeda T. Role of the clathrin adaptor PICALM in normal hematopoiesis and polycythemia vera pathophysiology. Haematologica. 2015 Apr; 100(4):439-51. PMID: 25552701; PMCID: PMC4380716.
  14. Bender M, Giannini S, Grozovsky R, Jönsson T, Christensen H, Pluthero FG, Ko A, Mullally A, Kahr WH, Hoffmeister KM, Falet H. Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice. Blood. 2015 Feb 05; 125(6):1014-24. PMID: 25468568; PMCID: PMC4319232.
  15. Chen E, Mullally A. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms? Hematology Am Soc Hematol Educ Program. 2014 Dec 05; 2014(1):268-76. PMID: 25696866.
    View in: PubMed
  16. Lane SW, Mullally A. Hit the spleen, JAK! Blood. 2014 Nov 06; 124(19):2898-900. PMID: 25377558.
    View in: PubMed
  17. Chen E, Ahn JS, Massie CE, Clynes D, Godfrey AL, Li J, Park HJ, Nangalia J, Silber Y, Mullally A, Gibbons RJ, Green AR. JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response. Proc Natl Acad Sci U S A. 2014 Oct 21; 111(42):15190-5. PMID: 25288776; PMCID: PMC4210350.
  18. Chen E, Schneider RK, Breyfogle LJ, Rosen EA, Poveromo L, Elf S, Ko A, Brumme K, Levine R, Ebert BL, Mullally A. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood. 2015 Jan 08; 125(2):327-35. PMID: 25281607; PMCID: PMC4287639.
  19. Schneider RK, Ademà V, Heckl D, Järås M, Mallo M, Lord AM, Chu LP, McConkey ME, Kramann R, Mullally A, Bejar R, Solé F, Ebert BL. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell. 2014 Oct 13; 26(4):509-20. PMID: 25242043; PMCID: PMC4199102.
  20. De Vita S, Schneider RK, Garcia M, Wood J, Gavillet M, Ebert BL, Gerbaulet A, Roers A, Levine RL, Mullally A, Williams DA. Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. PLoS One. 2014; 9(5):e96209. PMID: 24788138; PMCID: PMC4008566.
  21. Järås M, Miller PG, Chu LP, Puram RV, Fink EC, Schneider RK, Al-Shahrour F, Peña P, Breyfogle LJ, Hartwell KA, McConkey ME, Cowley GS, Root DE, Kharas MG, Mullally A, Ebert BL. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. J Exp Med. 2014 Apr 07; 211(4):605-12. PMID: 24616378; PMCID: PMC3978274.
  22. Mullally A, Ebert BL. Sinister symbiosis: pathological hematopoietic-stromal interactions in CML. Cell Stem Cell. 2013 Sep 05; 13(3):257-8. PMID: 24012363; PMCID: PMC3842099.
  23. Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, Austin R, Heckl D, Breyfogle LJ, Kuhn CP, Kalaitzidis D, Armstrong SA, Williams DA, Hill GR, Ebert BL, Lane SW. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-a in a murine model of polycythemia vera. Blood. 2013 May 02; 121(18):3692-702. PMID: 23487027; PMCID: PMC3643767.
  24. Mullally A, Ebert BL. Janus reveals another face: the biologic rationale for targeting Janus kinase 2 in lymphoma. J Clin Oncol. 2012 Nov 20; 30(33):4168-70. PMID: 22965959.
    View in: PubMed
  25. Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012 Sep 06; 489(7414):155-9. PMID: 22820254; PMCID: PMC3991463.
  26. Mullally A, Lane SW, Brumme K, Ebert BL. Myeloproliferative neoplasm animal models. Hematol Oncol Clin North Am. 2012 Oct; 26(5):1065-81. PMID: 23009938; PMCID: PMC3459181.
  27. Lin X, Rice KL, Buzzai M, Hexner E, Costa FF, Kilpivaara O, Mullally A, Soares MB, Ebert BL, Levine R, Licht JD. miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation. Leukemia. 2013 Feb; 27(2):344-52. PMID: 22864358.
    View in: PubMed
  28. Mullally A, Poveromo L, Schneider RK, Al-Shahrour F, Lane SW, Ebert BL. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. Blood. 2012 Jul 05; 120(1):166-72. PMID: 22627765; PMCID: PMC3390954.
  29. Wernig G, Kharas MG, Mullally A, Leeman DS, Okabe R, George T, Clary DO, Gilliland DG. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012 Apr; 26(4):720-7. PMID: 22005786.
    View in: PubMed
  30. Kumar MS, Narla A, Nonami A, Mullally A, Dimitrova N, Ball B, McAuley JR, Poveromo L, Kutok JL, Galili N, Raza A, Attar E, Gilliland DG, Jacks T, Ebert BL. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Blood. 2011 Oct 27; 118(17):4666-73. PMID: 21873545; PMCID: PMC3208282.
  31. Tefferi A, Abdel-Wahab O, Cervantes F, Crispino JD, Finazzi G, Girodon F, Gisslinger H, Gotlib J, Kiladjian JJ, Levine RL, Licht JD, Mullally A, Odenike O, Pardanani A, Silver RT, Solary E, Mughal T. Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood Cancer J. 2011 Mar 04; 1:e7. PMID: 23471017; PMCID: PMC3255279.
  32. Mullally A, Ebert BL. STATistical power of clonal analysis: differential STAT1 pathway activation downstream of the JAK2V617F mutation. Cancer Cell. 2010 Nov 16; 18(5):405-6. PMID: 21075304; PMCID: PMC3001244.
  33. Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian C, Wilson FH, Currie T, Khanna-Gupta A, Berliner N, Kutok JL, Ebert BL. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood. 2011 Mar 03; 117(9):2567-76. PMID: 21068437; PMCID: PMC3062351.
  34. Mullally A, Ebert BL. NF1 inactivation revs up Ras in adult acute myelogenous leukemia. Clin Cancer Res. 2010 Aug 15; 16(16):4074-6. PMID: 20587590.
    View in: PubMed
  35. Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, Paktinat M, Haydu JE, Housman E, Lord AM, Wernig G, Kharas MG, Mercher T, Kutok JL, Gilliland DG, Ebert BL. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010 Jun 15; 17(6):584-96. PMID: 20541703; PMCID: PMC2909585.
  36. Housman E, Chang P, Lane SW, Blinder R, Galinsky I, Kesari S, Ho VT, Stone RM, Mullally A. CNS relapse in acute promyeloctyic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):e409-11. PMID: 20530270.
    View in: PubMed
  37. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009 Jul 02; 114(1):144-7. PMID: 19420352; PMCID: PMC2710942.
  38. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, Bass A, Marubayashi S, Heguy A, Garcia-Manero G, Kantarjian H, Offit K, Stone RM, Gilliland DG, Klein RJ, Levine RL. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009 Apr; 41(4):455-9. PMID: 19287384; PMCID: PMC3676425.
  39. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Finke CM, Mullally A, Li CY, Pardanani A, Gilliland DG. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009 May; 23(5):900-4. PMID: 19262599; PMCID: PMC4654631.
  40. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, Levine RL. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009 May; 23(5):905-11. PMID: 19262601; PMCID: PMC4654629.
  41. Mullally A, Ritz J. Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood. 2007 Feb 15; 109(4):1355-62. PMID: 17008540.
    View in: PubMed
  42. Mullally AM, Vogelsang GB, Moliterno AR. Wasted sheep and premature infants: the role of trace metals in hematopoiesis. Blood Rev. 2004 Dec; 18(4):227-34. PMID: 15501551.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Mullally's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_